Dr. Carla Staresinic is a pharmacist who is specialized in Pharmacotherapy in Madison, Wisconsin. Patients can reach her at 2500 Overlook Terrace, Pharmacy (119), Madison or contact her on 608-256-1901. Active license number of Dr. Carla Staresinic is 044734 for Pharmacotherapy in Missouri. Dr. Carla Staresinic is a licensed pharmacist who has demonstrated specialized knowledge and skill in optimizing pharmacotherapeutic care of patients, by developing, implementing, monitoring, and modifying complex treatment plans, providing advanced level education and consultation, and collaborating with other health professionals in the management of therapy.
Complete Profile:
Dr. Carla Staresinic speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Carla Staresinic are as mentioned below.
NPI Number:
1477648855
NPI Enumeration Date:
03 Oct, 2006
NPI Last Update On:
11 Jul, 2007
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Carla Staresinic are as mentioned below.
Specialization
License Number
State
Status
Pharmacotherapy
044734
Missouri
Primary
Pharmacotherapy
Illinois
Secondary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
6733 Gaylord Nelson Rd., Middleton, Wisconsin
Zip:
53562
Phone Number:
--
Fax Number:
--
Patients can reach Dr. Carla Staresinic at 2500 Overlook Terrace, Pharmacy (119), Madison, Wisconsin or can call on phone at 608-256-1901.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.